The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. [electronic resource]
Producer: 20160218Description: e0126615 p. digitalISSN:- 1932-6203
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- B-Lymphocytes -- metabolism
- Cyclophosphamide -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Ki-1 Antigen -- immunology
- Ki-67 Antigen -- metabolism
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Multivariate Analysis
- Prednisone -- administration & dosage
- Prognosis
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Retrospective Studies
- Rituximab -- administration & dosage
- Treatment Outcome
- Vincristine -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.